Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Cagrilintide with Semaglutide in Overweight or Obesity
NCT03600480Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing Cagrilintide + Semaglutide with Placebo + Semaglutide (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Jul 2018; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03600480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600480.